Case Details
- Citation: [2012] SGHC 16
- Case Title: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd
- Court: High Court of the Republic of Singapore
- Decision Date: 19 January 2012
- Case Number: Suit No 416 of 2011 (Summons 5001/2011/M)
- Coram: Chan Wei Sern Paul AR
- Procedural Application: Defendant’s application to strike out the plaintiff’s Statement of Claim (Amendment No. 1) under O 18 r 19 of the Rules of Court (Cap 322, R 5, 2006 Rev Ed)
- Plaintiff/Applicant: AstraZeneca AB (SE)
- Defendant/Respondent: Sanofi-Aventis Singapore Pte Ltd
- Counsel for Plaintiff: Lee Ai Ming, Alvin Lim and Sandeep Menon (Rodyk & Davidson LLP)
- Counsel for Defendant: Vignesh Vaerhn, Eunice Lim and Tan Lijun (Allen & Gledhill LLP)
- Legal Areas: Patents and Inventions – Infringement; Civil Procedure – Pleadings – Striking Out
- Key Statutory Provision: Section 12A of the Medicines Act (Cap 176, 1985 Rev Ed) (enacted in 2004)
- Related Regulatory Framework: Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed), including the Sixth Schedule and regulation 5B
- Judgment Length: 15 pages, 8,110 words
Summary
This High Court decision concerns the interaction between Singapore’s patent regime and the “patent linkage” style notification and licensing framework introduced through section 12A of the Medicines Act. AstraZeneca, the proprietor of Singapore Patent No. 89993 relating to pharmaceutical compositions comprising rosuvastatin calcium and a specific stabiliser, sued Sanofi after Sanofi applied to the Health Sciences Authority (HSA) for product licences for rosuvastatin calcium tablets. AstraZeneca’s suit was framed as a pre-emptive action under section 12A, seeking declarations and injunctive relief on the basis that Sanofi’s proposed products would infringe the patent if licensed and commercialised.
The defendant applied to strike out the amended Statement of Claim on the grounds that it disclosed no reasonable cause of action, was frivolous or vexatious, and/or was an abuse of process. The court accepted that striking out is a serious step but emphasised that pleadings must disclose a real and arguable case. The court’s reasoning turned on the nature of section 12A: while it creates a procedural mechanism linked to product licensing and a 30-month stay, it does not dispense with the need for a substantive basis for infringement allegations. Critically, AstraZeneca conceded it had no evidence that Sanofi had committed any act of infringement, and it did not file affidavit evidence to support its contention that the proposed formulation necessarily contained the claimed stabiliser.
Ultimately, the court granted the defendant’s application and struck out the claim. The practical effect was that AstraZeneca could not use section 12A as a substitute for a properly pleaded and supported infringement case, nor could it rely on mere disbelief of the defendant’s non-infringement position to sustain litigation aimed primarily at obtaining the licensing moratorium.
What Were the Facts of This Case?
AstraZeneca AB (SE) is a Swedish company engaged in the research, development, manufacture and commercialisation of healthcare products. Sanofi-Aventis Singapore Pte Ltd is a Singapore company similarly engaged in healthcare product development and commercialisation. AstraZeneca is the owner of Singapore Patent No. 89993, titled “Pharmaceutical Compositions Comprising a HMG COA Reductase Inhibitor”. The patent’s invention, as reflected in claim 5, is directed to a pharmaceutical composition comprising (1) an active ingredient—rosuvastatin calcium—and (2) an inorganic salt stabiliser in which the cation is multivalent. The stabiliser requirement is central: the claim specifies “an inorganic salt in which the cation is multivalent” as a stabilising agent.
On 1 April 2011, Sanofi applied to the HSA for product licences for three “Proposed Products”: Rosucard film-coated tablets in 10 mg, 20 mg and 40 mg strengths. Under section 5 of the Medicines Act, a product licence is required to sell, supply or export medicinal products, or to procure the manufacture or assembly of medicinal products for sale, supply or export. In its application forms, Sanofi disclosed that a patent was in force in respect of the Proposed Products, that Sanofi was not the patent proprietor, and that the proprietor had not consented to or acquiesced in the grant of product licences. Sanofi also stated, in its opinion and to the best of its belief, that the patent would not be infringed by the acts for which the licences were sought.
Following this, the HSA requested Sanofi to serve a notice to AstraZeneca using a form in the Sixth Schedule to the Medicines (Licensing, Standard Provisions and Fees) Regulations. Sanofi served the notice on 19 April 2011. In the notice, Sanofi reiterated that it believed the patent would not be infringed because its proposed composition did not comprise the claimed stabiliser: specifically, it did not contain “an inorganic salt in which the cation is multivalent”. The notice also informed AstraZeneca that if AstraZeneca did not apply within 45 days for a court order restraining the act for which the licence was applied, or for a declaration by the Registrar of Patents that the patent would be infringed, the HSA could proceed to grant the licence.
Section 12A(5) of the Medicines Act, read with regulation 5B(3) of the Regulations, provides that if the patent proprietor makes the application within the 45-day period, the HSA must enforce a 30-month stay on processing the product licence applications. AstraZeneca filed its original Statement of Claim on 10 June 2011, which had the practical effect of initiating the 30-month moratorium. There was a dispute as to whether the action was commenced within the 45-day period, but the court indicated that this was not material for the present striking-out application.
In its final form, AstraZeneca sought declarations that Sanofi’s acts in Singapore—disposal, offering to dispose, using, importing, and keeping the products—would infringe claims 1 to 27 of the patent, and sought an injunction restraining Sanofi from infringing the patent. However, AstraZeneca did not file particulars of infringement. When Sanofi sought further particulars, the court record indicates that AstraZeneca considered the request misconceived and did not provide the requested particulars. AstraZeneca’s suit, therefore, proceeded without detailed infringement particulars and, as later conceded, without evidence of any actual infringement by Sanofi.
What Were the Key Legal Issues?
The central legal issues were procedural and substantive. Procedurally, the court had to decide whether AstraZeneca’s amended Statement of Claim should be struck out under O 18 r 19 of the Rules of Court. That requires the court to assess whether the pleading discloses no reasonable cause of action, is frivolous or vexatious, or is otherwise an abuse of process. In patent-related litigation, this inquiry often overlaps with whether the claim is properly framed and whether it has a real prospect of success.
Substantively, the case raised an important question about the scope and function of section 12A of the Medicines Act. AstraZeneca argued that section 12A provides a separate and independent cause of action, enabling the patent proprietor to test whether a proposed product would infringe the patent on the assumption that the defendant would carry out the acts for which the product licences were sought. In other words, AstraZeneca characterised the action as pre-emptive and not dependent on proof of past infringement.
Sanofi’s position was narrower. It argued that section 12A does not create an independent substantive cause of action separate from patent infringement proceedings under the Patents Act. On Sanofi’s view, section 12A is essentially a notification mechanism that triggers a stay, but any substantive infringement challenge must still be pursued under the Patents Act framework. Sanofi further argued that even if section 12A could support a separate action, AstraZeneca’s pleading lacked a sufficient factual basis: mere disbelief of Sanofi’s non-infringement explanation was not enough to sustain a claim.
How Did the Court Analyse the Issues?
The court began by setting out the procedural standard for striking out pleadings. While the judgment excerpt provided is truncated after the general statement that the law is not disputed and that the court would be brief, the court’s approach is clear from the way it applied the striking-out framework to AstraZeneca’s pleadings. The court treated the application as requiring it to examine whether AstraZeneca’s Statement of Claim disclosed a reasonable cause of action and whether it was properly pleaded rather than speculative or tactical.
On the substantive question, the court focused on the nature of AstraZeneca’s claim and the evidence (or lack of evidence) supporting it. AstraZeneca conceded that it was not bringing a patent infringement action under the Patents Act and also conceded that it had no evidence that Sanofi had committed any act of infringement. This concession mattered because it underscored that AstraZeneca was not alleging a completed infringement event. Instead, AstraZeneca sought declarations and injunctive relief based on anticipated infringement arising from the licensing and subsequent commercialisation of the Proposed Products.
In that context, the court scrutinised AstraZeneca’s reliance on section 12A. AstraZeneca’s theory was that section 12A allows the patent proprietor to test future infringement by forcing disclosure through discovery and by challenging the defendant’s composition. However, the court noted that AstraZeneca’s only real basis for its claim was its belief that Sanofi’s formulation must necessarily include a stabiliser meeting the patent’s multivalent-cation inorganic salt requirement. AstraZeneca argued that it is “impossible” to use rosuvastatin calcium without using such a stabiliser. Yet, the court record indicates that AstraZeneca did not file affidavit evidence to support this assertion. The absence of evidential support became a key weakness in the pleading.
The court also addressed the defendant’s argument that the only act Sanofi had done in Singapore was to apply for product licences, and that such an application is not itself an infringing act. Sanofi relied on the principle from Upjohn v Kerfoot, where the court held that certain regulatory steps do not necessarily amount to infringement. While AstraZeneca attempted to avoid the Patents Act infringement framework by invoking section 12A, the court’s reasoning suggests that it would not allow section 12A to be used to circumvent the need for a substantive infringement foundation. Put differently, the court treated section 12A as procedural in its operation—linked to licensing and the stay—rather than as a mechanism that automatically converts a speculative dispute into a viable infringement claim.
Further, the court considered AstraZeneca’s litigation posture. AstraZeneca did not provide particulars of infringement, resisted requests for further particulars, and did not file an affidavit to support its factual assertions. In striking-out applications, courts are cautious not to decide contested facts prematurely; however, where a claimant’s case rests on assertions that are not pleaded with sufficient clarity or supported by evidence, the court may conclude that the claim lacks a reasonable cause of action. Here, AstraZeneca’s claim was effectively built on an inference that the Proposed Products must contain the claimed stabiliser, without the factual groundwork needed to make that inference more than conjecture.
Although the excerpt does not reproduce the court’s full reasoning on the precise interpretation of section 12A, the outcome indicates that the court did not accept AstraZeneca’s broad characterisation of section 12A as granting an independent right to litigate future infringement without the usual infringement evidential and pleading requirements. The court’s approach reflects a balancing exercise: section 12A is designed to protect patent proprietors from regulatory “workarounds” that would undermine patent rights, but it is not intended to permit patent proprietors to commence litigation purely to obtain the 30-month stay without a properly arguable infringement case.
What Was the Outcome?
The High Court granted Sanofi’s summons and struck out AstraZeneca’s amended Statement of Claim. The practical effect was that AstraZeneca’s attempt to secure declarations and injunctive relief based on anticipated infringement under section 12A could not proceed in the form pleaded.
For AstraZeneca, the decision meant that it could not rely on section 12A litigation as a standalone substitute for a properly pleaded and supported infringement case. For Sanofi, it meant that the proceedings were terminated at an early stage, preventing the dispute from continuing through discovery and trial on the basis of speculative infringement allegations.
Why Does This Case Matter?
AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd is significant for practitioners because it clarifies the limits of section 12A of the Medicines Act as a litigation tool. While section 12A is central to the patent linkage framework and provides a mechanism for a 30-month stay of HSA processing, the case demonstrates that the patent proprietor must still plead and support a real infringement case. The court will not treat section 12A as a licence to litigate future infringement on the basis of mere disbelief or unsupported assertions.
From a pleading strategy perspective, the decision underscores the importance of particulars of infringement and evidential support, even in a pre-emptive regulatory context. Where the claimant’s theory depends on technical composition facts—such as whether a stabiliser meets a specific chemical definition—courts expect the claimant to do more than assert impossibility or inevitability. The absence of affidavit evidence and the refusal to engage with requests for further particulars were key features that weakened AstraZeneca’s case.
For defendants, the case provides a procedural pathway to challenge weak or tactical section 12A claims via striking out. For patent proprietors, it signals that early litigation must be grounded in a coherent infringement theory and supported by at least a plausible factual basis. In practice, this may require technical analysis, expert input, and careful drafting of the claim and particulars to show why the proposed product is likely to fall within the patent claims.
Legislation Referenced
- Medicines Act (Cap 176, 1985 Rev Ed), including section 12A
- Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed), including the Sixth Schedule and regulation 5B(3)
- Patents Act (Cap 221, 2005 Rev Ed), including sections 66 and 67 (as discussed in submissions)
- Supreme Court of Judicature Act (Cap 322) (as referenced in the procedural context)
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), O 18 r 19 (striking out)
Cases Cited
- [1988] FSR 1 — The Upjohn Company v T. Kerfoot & Co. Ltd
- [2002] SGHC 238
- [2012] SGHC 16 (this case)
Source Documents
This article analyses [2012] SGHC 16 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.